Advertisement

Involvement of Aryl Hydrocarbon Receptor in l-Kynurenine-Mediated Parathyroid Hormone–Related Peptide Expression

  • Zhiqing DuanEmail author
  • Jiangong Lu
Original Paper
  • 18 Downloads

Abstract

Parathyroid hormone-related peptide (PTHrP), produced by specific cancers such as lung cancer, profoundly influences the formation of bone metastatic lesions via the “vicious cycle” of tumor growth and bone resorption. The changes in gene expression regulated by the abnormal microenvironment components play key roles in maintaining the biological characteristics of cells, such as the organotropism of cancer metastasis. A recent study has shown that l-kynurenine (l-Kyn), one of microenvironment components, induced a substantial increase in the metastasis of lung cancer cells. What remains unclear, however, is the linkage between l-Kyn and bone metastatic lesions. In the present paper, we found that a significant upregulation of PTHrP expression was detected when 95D cells, a lung cancer cell line, were incubated with 50 μM of l-Kyn. Meanwhile, l-Kyn (50/100 μM) strongly strengthened aryl hydrocarbon receptor (Ahr) expression. Additionally, l-Kyn (50 μM) increased the expression of the nuclear translocation of Ahr and cytochrome P450 1A1. Most importantly, the l-Kyn-induced upregulation of migration was significantly reduced when cells were co-incubated with siRNAAhr. Notably, the l-Kyn-mediated increase in PTHrP was also substantially attenuated upon siRNAAhr treatment in 95D cells. These results suggest that Ahr is involved in the l-Kyn-induced enhancement of PTHrP expression.

Keywords

L-kynurenine Bone metastatic lesions Parathyroid hormone-related peptide Aryl hydrocarbon receptor 

Notes

Authors’ Contribution

Zhiqing Duan participated in the study design, performed partly experiments, drafted the manuscript, and analyzed the data. Jiangong Lu performed partly experiments and analyzed the data.

Funding Information

This study was supported by the Foundation of Shanxi Educational Committee (Grant No. 201802057), the Youth Research Fund of Shanxi Medical University (Grant No. 02201518), and the Youth Research Fund of Shanxi Province (Grant No. 201601D021169).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Research Involving Human Participants and/or Animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

12672_2019_357_MOESM1_ESM.doc (66 kb)
ESM 1 (DOC 65 kb)

References

  1. 1.
    Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331:1559–1564CrossRefGoogle Scholar
  2. 2.
    Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147:275–292CrossRefGoogle Scholar
  3. 3.
    Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593CrossRefGoogle Scholar
  4. 4.
    Seton-Rogers S (2013) Tumour microenvironment: teaching old macrophages new tricks. Nat Rev Cancer 13:753CrossRefGoogle Scholar
  5. 5.
    Qian B-Z, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39–51CrossRefGoogle Scholar
  6. 6.
    Psaila B, Lyden D (2009) The metastatic niche: adapting the foreign soil. Nat Rev Cancer 9:285–293CrossRefGoogle Scholar
  7. 7.
    Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9:239–252CrossRefGoogle Scholar
  8. 8.
    Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269–1274CrossRefGoogle Scholar
  9. 9.
    Zamanakou M, Germenis AE, Karanikas V (2007) Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett 111:69–75CrossRefGoogle Scholar
  10. 10.
    Wang Y, Hu GF, Wang ZH (2017) The status of immunosuppression in patients with stage III B or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy. OncoTargets Ther 10:3557–3566CrossRefGoogle Scholar
  11. 11.
    Song H, Park H, Kim YS, Kim KD, Lee HK, Cho DH, Yang JW, Hur DY (2011) L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species. Int Immunopharmacol 11:932–938CrossRefGoogle Scholar
  12. 12.
    Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA (2010) An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185:3190–3198CrossRefGoogle Scholar
  13. 13.
    Duan Z, Duan Y, Lei H, Hu N, Shi J, Shen D, Wang X, Hu Y (2014) Attenuation of antigenic immunogenicity by kynurenine, a novel suppressive adjuvant. Hum Vaccin Immunother 10:1295–1305CrossRefGoogle Scholar
  14. 14.
    Duan ZQ, Shi JD, Wu MN, Hu NZ, Hu YZ (2016) Influence of miR-30b regulating humoral immune response by genetic difference. Immunol Res 64:181–190CrossRefGoogle Scholar
  15. 15.
    Duan ZQ, Li Y, Li L (2017) Experimental evidences for miR-30b as a negative regulator of FOXO3 upregulated by kynurenine. Immunol Res 65:1074–1082CrossRefGoogle Scholar
  16. 16.
    Schulte KW, Green E, Wilz A, Platten M, Daumke O (2017) Structural basis for aryl hydrocarbon receptor-mediated gene activation. Structure 25:1025–1033.e3CrossRefGoogle Scholar
  17. 17.
    Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478:197–203CrossRefGoogle Scholar
  18. 18.
    Reyes-Reyes EM, Ramos IN, Tavera-Garcia MA, Ramos KS (2016) The aryl hydrocarbon receptor agonist benzo(a)pyrene reactivates LINE-1 in HepG2 cells through canonical TGF-β1 signaling: implications in hepatocellular carcinogenesis. Am J Cancer Res 6:1066–1077PubMedPubMedCentralGoogle Scholar
  19. 19.
    Kollara A, Brown TJ (2010) Four and a half LIM domain 2 alters the impact of aryl hydrocarbon receptor on androgen receptor transcriptional activity. J Steroid Biochem Mol Biol 118:51–58CrossRefGoogle Scholar
  20. 20.
    Narasimhan S, Stanford Zulick E, Novikov O, Parks A, Schlezinger J, Wang Z, Laroche F, Feng H, Mulas F, Monti S, Sherr D (2018) Towards resolving the pro- and anti-tumor effects of the aryl hydrocarbon receptor. Int J Mol Sci 19Google Scholar
  21. 21.
    Langley RR, Fidler IJ (2011) The seed and soil hypothesis revisited – the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 128:2527–2535CrossRefGoogle Scholar
  22. 22.
    Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345–357CrossRefGoogle Scholar
  23. 23.
    Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise TA (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197–206CrossRefGoogle Scholar
  24. 24.
    Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, Nakamura Y, Inui N, Nakamura H, Chida K (2010) Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67:361–365CrossRefGoogle Scholar
  25. 25.
    Zhu Y, Zhu Y, Yao S et al (2011) Cell surface signaling molecules in the control of immune responses: a tide model. Immunity 34:466–478CrossRefGoogle Scholar
  26. 26.
    Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, Finn A, Bhat M, Samuelsson M, Lundberg K, Dahl ML, Sellgren C, Schuppe-Koistinen I, Svensson C, Erhardt S, Engberg G (2015) Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway. J Psychiatry Neurosci 40:126–133PubMedPubMedCentralGoogle Scholar
  27. 27.
    Vacher S, Castagnet P, Chemlali W, Lallemand F, Meseure D, Pocard M, Bieche I, Perrot-Applanat M (2018) High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism. PLoS One 13:e0190619CrossRefGoogle Scholar
  28. 28.
    Chen JY, Li CF, Kuo CC, Tsai KK, Hou MF, Hung WC (2014) Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression. Breast Cancer Res 16:410CrossRefGoogle Scholar
  29. 29.
    Novikov O, Wang Z, Stanford EA, Parks AJ, Ramirez-Cardenas A, Landesman E, Laklouk I, Sarita-Reyes C, Gusenleitner D, Li A, Monti S, Manteiga S, Lee K, Sherr DH (2016) An aryl hydrocarbon receptor-mediated amplification loop that enforces cell migration in ER-/PR-/Her2-human breast cancer cells. Mol Pharmacol 90:674–688CrossRefGoogle Scholar
  30. 30.
    Tarnow P, Bross S, Wollenberg L, Nakajima Y, Ohmiya Y, Tralau T, Luch A (2017) A novel dual-color luciferase reporter assay for simultaneous detection of estrogen and aryl hydrocarbon receptor activation. Chem Res Toxicol 30:1436–1447CrossRefGoogle Scholar
  31. 31.
    Chang JT, Chang H, Chen PH, Lin SL, Lin P (2007) Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin Cancer Res 13:38–45CrossRefGoogle Scholar
  32. 32.
    Schlezinger JJ, Liu D, Farago M, Seldin DC, Belguise K, Sonenshein GE, Sherr DH (2006) A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biol Chem 387:1175–1187CrossRefGoogle Scholar
  33. 33.
    Yang X, Solomon S, Fraser LR, Trombino AF, Liu D, Sonenshein GE, Hestermann EV, Sherr DH (2008) Constitutive regulation of CYP1B1 by the aryl hydrocarbon receptor (AhR) in pre-malignant and malignant mammary tissue. J Cell Biochem 104:402–417CrossRefGoogle Scholar
  34. 34.
    Yang X, Liu D, Murray TJ, Mitchell GC, Hesterman EV, Karchner SI, Merson RR, Hahn ME, Sherr DH (2005) The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cells. Oncogene 24:7869–7881CrossRefGoogle Scholar
  35. 35.
    Miret N, Pontillo C, Ventura C, Carozzo A, Chiappini F, Kleiman de Pisarev D, Fernández N, Cocca C, Randi A (2016) Hexachlorobenzene modulates the crosstalk between the aryl hydrocarbon receptor andtransforming growth factor-β1 signaling, enhancing human breast cancer cell migration and invasion. Toxicology 366-367:20–31CrossRefGoogle Scholar
  36. 36.
    Zhang J, Zhang H, Liu J, Tu X, Zang Y, Zhu J, Chen J, Dong L, Zhang J (2012) miR-30 inhibits TGF-β1-induced epithelial-to-mesenchymal transition in hepatocyte by targeting Snail1. Biochem Biophys Res Commun 417:1100–1105CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Biochemistry and Molecular Biology, School of Basic Medical SciencesShanxi Medical UniversityTaiyuanPeople’s Republic of China
  2. 2.The Second Hospital of Shanxi Medical UniversityTaiyuanPeople’s Republic of China

Personalised recommendations